4-甲基噻唑-5-磺酰氯 | 953070-51-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基噻唑-5-磺酰氯
• 英文名称: 4-methylthiazole-5-sulphonyl chloride
• 英文别名: 4-methylthiazole-5-sulfonyl chloride；4-Methyl-1,3-thiazole-5-sulfonyl chloride
• CAS: 953070-51-4
• 化学式: C₄H₄ClNO₂S₂
• mdl: MFCD09864968
• 分子量: 197.666
• InChiKey: AWTJUYXVSWZCIK-UHFFFAOYSA-N

物化性质

• 熔点：
  34-36°

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  83.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-甲基噻唑-5-磺酰氯 、 5-(5-(5-aminopyridin-3-yl)thiophen-2-yl)-2-methylisoindolin-1-one 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以12%的产率得到4-methyl-N-(5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)thiazole-5-sulphonamide
  参考文献：
  名称：

  Substituted arylsulphonamides as inhibitors of perforin-mediated lysis

  摘要：

  The structure-activity relationships for a series of arylsulphonamide-based inhibitors of the pore forming protein perforin have been explored. Perforin is a key component of the human immune response, however inappropriate activity has also been implicated in certain auto-immune and therapy induced conditions such as allograft rejection and graft versus host disease. Since perforin is expressed exclusively by cells of the immune system, inhibition of this protein would be a highly selective strategy for the immunosuppressive treatment of these disorders. Compounds from this series were demonstrated to be potent inhibitors of the lytic action of both isolated recombinant perforin and perforin secreted by natural killer cells in vitro. Several potent and soluble examples were assessed for in vivo pharmacokinetic properties and found to be suitable for progression to an in vivo model of transplant rejection. (C) 2017 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2017.05.048
• 作为产物：
  描述：

  4-甲基噻唑 在 氯磺酸 、 五氯化磷 作用下， 反应 4.0h， 以12%的产率得到4-甲基噻唑-5-磺酰氯
  参考文献：
  名称：

  QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS

  摘要：

  本发明涉及抑制诱导型NOS合酶的新奎诺酮化合物（化学式I），以及合成和使用这些化合物的方法，包括通过向患者施用这些化合物来治疗疾病的抑制或调节一氧化氮合成和/或降低一氧化氮水平的方法。

  公开号：

  US20080139558A1

文献信息

• [EN] DIARYLHYDANTOIN COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DIARYLHYDANTOINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NUVATION BIO INC

  公开号：WO2020113088A1

  公开（公告）日：2020-06-04

  The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation. The present disclosure provides compounds having hormone receptor antagonist activity. These compounds can be useful in treating cancer, in particular those cancers which can be potentiated by AR and/or GR antagonism.

  该披露涉及从核类固醇受体结合物中衍生的抗癌化合物，以及含有这些化合物的产品，以及它们的使用和制备方法。本披露提供具有激素受体拮抗活性的化合物。这些化合物可用于治疗癌症，特别是那些可以通过雄激素受体和/或糖皮质激素受体拮抗增强的癌症。
• Substituted arylsulphonamides as inhibitors of perforin-mediated lysis
  作者：Julie A. Spicer、Christian K. Miller、Patrick D. O'Connor、Jiney Jose、Kristiina M. Huttunen、Jagdish K. Jaiswal、William A. Denny、Hedieh Akhlaghi、Kylie A. Browne、Joseph A. Trapani

  DOI：10.1016/j.ejmech.2017.05.048

  日期：2017.9

  The structure-activity relationships for a series of arylsulphonamide-based inhibitors of the pore forming protein perforin have been explored. Perforin is a key component of the human immune response, however inappropriate activity has also been implicated in certain auto-immune and therapy induced conditions such as allograft rejection and graft versus host disease. Since perforin is expressed exclusively by cells of the immune system, inhibition of this protein would be a highly selective strategy for the immunosuppressive treatment of these disorders. Compounds from this series were demonstrated to be potent inhibitors of the lytic action of both isolated recombinant perforin and perforin secreted by natural killer cells in vitro. Several potent and soluble examples were assessed for in vivo pharmacokinetic properties and found to be suitable for progression to an in vivo model of transplant rejection. (C) 2017 The Authors. Published by Elsevier Masson SAS.
• QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS
  申请人：Smith Nicholas D.

  公开号：US20080139558A1

  公开（公告）日：2008-06-12

  The present invention relates to novel quinolones of Formula I that inhibit inducible NOS synthase together with methods of synthesizing and using the compounds including methods for inhibiting or modulating nitric oxide synthesis and/or lowering nitric oxide levels in a patient by administering the compounds for the treatment of disease.

  本发明涉及抑制诱导型NOS合酶的新奎诺酮化合物（化学式I），以及合成和使用这些化合物的方法，包括通过向患者施用这些化合物来治疗疾病的抑制或调节一氧化氮合成和/或降低一氧化氮水平的方法。